Analyser av Pharma Equity

Pharma Equity Group - Strengthened Balance Sheet Facilitates Continued Development - Analyst Group

Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding through a directed share issue, with a s...

Analyst Group • 19 Nov 12:26

Analyst Group Comments on PEG’s Q3 Report for 2024

Pharma Equity Group (“PEG” or “the Company”) published its Q3 report for 2024 on the 15th of November 2024.

Analyst Group • 15 Nov 12:55

Analyst Group Comment on Pharma Equity Group’s obtained patent protection in Japan for RNX-051

Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, October the 23rd, that the Company’s subsidiary Reponex Pharmaceuticals...

Analyst Group • 23 Oct 12:08

Analyst Group Comment on Pharma Equity Group’s Directed Share Issue to a Premium

Pharma Equity Group (“PEG” or “the Company”) announced on Friday, October 4th, that the Company’s board of directors has resolved to issue 2...

Analyst Group • 08 Oct 08:55

Pharma Equity Group: Exploring Opportunities for a Capital Increase - Analyst Group

Pharma Equity Group (“PEG” or “the Company”) presented a Q2-report characterized by further advancements in the clinical development (RNX-05...

Analyst Group • 20 Aug 14:07

Analyst Group Comments on PEG’s Q2 Report for 2024

Pharma Equity Group (“PEG” or “the Company”) published its Q2 report for 2024 on the 16th of August 2024.

Analyst Group • 19 Aug 07:37

Pharma Equity Group: Aims to Strengthening the Company’s Financial Position - Analyst Group

Pharma Equity Group (“PEG” or “the Company”) continues to make clinical progress, as demonstrated by the positive final results obtained fro...

Analyst Group • 20 May 11:50

Pharma Equity Group: Analyst Group Comments on PEG’s Q1 Report for 2024

Pharma Equity Group published its Q1 report for 2024 on the 16th of May, 2024.

Analyst Group • 16 May 13:15

Analyst Group comments on Pharma Equity Group’s Positive Final Results From the Phase II Trial of the Drug Candidate RNX-051

Pharma Equity Group (“PEG” or “the Company”) announced on Friday, April 5th, that the Company’s subsidiary Reponex Pharmaceuticals A/S (“Rep...

Analyst Group • 05 Apr 14:29

Pharma Equity Group: Clinical Development Progression and Strengthened IP-Portfolio - Analyst Group

Pharma Equity Group (“PEG” or “the Company”) presented a Q4-report marked by advancements in the clinical development, the addition of two w...

Analyst Group • 22 Mar 08:17

Analyst Group Comments on PEG’s Year-End Report for 2023

Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2023 on the 20th of March, 2024.

Analyst Group • 20 Mar 14:05

Pharma Equity Group’s Notification from the EPO Granting Their Patent for the Drug Candidate RNX-022 - Analyst Group

Pharma Equity Group (“PEG” or “the Company”) announced on Tuesday, March 5th, that the Company’s subsidiary Reponex Pharmaceuticals A/S (“Re...

Analyst Group • 05 Mar 12:50

Pharma Equity Group: A Pharma Company with Lower Risk but Equivalent Upside Potential - Analyst Group

Pharma Equity Group (“PEG” or “the Company”), through the Company’s subsidiary, Reponex, employs a drug repositioning strategy, which involv...

Analyst Group • 27 Feb 11:10

Analyst Group Initiates Equity Research Coverages of Pharma Equity Group

Analyst Group has entered into an agreement with Pharma Equity Group on commissioned research, including e.

Analyst Group • 05 Feb 13:48

Börskollen

För dig med koll på börsen